[1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.10.1016/S0278-2391(03)00720-1]Search in Google Scholar
[2. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws: 2009 update. J Oral Maxillofac Surg. 2009;67(5suppl):2-12.10.1016/j.joms.2009.01.009]Search in Google Scholar
[3. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw – 2014 update. J Oral Maxillofac Surg. 2014;72:1938-1956.10.1016/j.joms.2014.04.031]Search in Google Scholar
[4. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95:297-304.10.1016/0002-9343(93)90282-T]Search in Google Scholar
[5. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16:2038-2044.10.1200/JCO.1998.16.6.20389626201]Search in Google Scholar
[6. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882.10.1093/jnci/djh14115173273]Search in Google Scholar
[7. Berenson JR, Hillner BE, Kyle RA, et al. American society of clinical oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.10.1200/JCO.2002.06.03712202673]Search in Google Scholar
[8. Delmas PD. The use of bisphosphonates in the treatment of osteoporosis. Curr Opin Rheumatol. 2005;17:462-466.10.1097/01.bor.0000163448.51661.8715956844]Search in Google Scholar
[9. Medical economics. Physicians’ Desk Reference. 57th ed. Montvale, NJ: Medical Economics; 2003.]Search in Google Scholar
[10. Delmas PD, Meunier PJ. The management of Paget’s disease of bone. N Engl J Med. 1997;336:558-566.10.1056/NEJM1997022033608079023094]Search in Google Scholar
[11. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom. 2008;11:325-338.10.1016/j.jocd.2008.02.00218375161]Search in Google Scholar
[12. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011;377:813-822.10.1016/S0140-6736(10)62344-6]Search in Google Scholar
[13. Tenore G, Palaia G, Gaimari G, et al. Medication-Related Osteonecrosis of the Jaws (MRONJ): Etiological update. Senses Sci. 2014;1:147-152.]Search in Google Scholar
[14. Barasch A, Cunha-Cruz J, Curro FA, et al. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN. J Dent Res. 2011;90:439-444.10.1177/0022034510397196314412921317246]Search in Google Scholar
[15. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620-623.10.1111/j.1365-2141.2006.06230.x16889620]Search in Google Scholar
[16. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826-836.10.1359/jbmr.080205267708318558816]Search in Google Scholar
[17. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356-5362.10.1200/JCO.2009.21.958419805682]Search in Google Scholar
[18. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945-952.10.1200/JCO.2005.04.246516484704]Search in Google Scholar
[19. Kyrgidis A, Vahtsevanos K, Koloutsos G, et al. Bisphosphonate-related osteonecrosis of the jaws: a case-control study of risk factors in breast cancer patients. J Clin Oncol. 2008;26:4634-4638.10.1200/JCO.2008.16.276818574158]Search in Google Scholar
[20. Aguiar BD, Bohn SU, Cabrera Suarez MA, Aguiar MJ. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol. 2007;18:556-560.10.1093/annonc/mdl40817082512]Search in Google Scholar
[21. Lesclous P, Abi NS, Carrel JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation? Bone. 2009;45:843-852.]Search in Google Scholar
[22. Tsao C, Darby I, Ebeling PR, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg. 2013;71:1360-1366.10.1016/j.joms.2013.02.01623582590]Search in Google Scholar
[23. Jadu F, Lee L, Pharoah M, Reece D, Wang L. A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol. 2007;18:2015-2019.10.1093/annonc/mdm37017804475]Search in Google Scholar
[24. Thumbigere-Math V, Tu L, Huckabay S, et al. A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates. Am J Clin Oncol. 2012;35:386-392.10.1097/COC.0b013e3182155fcb22561331]Search in Google Scholar
[25. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol. 2012;23:1341-1347.10.1093/annonc/mdr43521986094]Search in Google Scholar
[26. Diz P, Lopez-Cedrun JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 2012;143:981-984.10.14219/jada.archive.2012.032322942143]Search in Google Scholar
[27. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27:694-701.10.1002/jbmr.1479341562022113951]Search in Google Scholar
[28. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11:401.10.1038/nrd370522543469]Search in Google Scholar
[29. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23:4925.10.1200/JCO.2005.06.09115983391]Search in Google Scholar
[30. Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352:373.10.1056/NEJMcp04280615673803]Search in Google Scholar
[31. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132.10.1200/JCO.2010.29.710121060033]Search in Google Scholar
[32. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125.10.1200/JCO.2010.31.330421343556]Search in Google Scholar
[33. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res. 2007;86:1022.10.1177/15440591070860110217959891]Search in Google Scholar
[34. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011;48:677.10.1016/j.bone.2010.11.020]Search in Google Scholar
[35. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci. 2006;100:189.10.1254/jphs.FMJ05004X2]Search in Google Scholar
[36. Ito M, Amizuka N, Nakajima T, Ozawa H. Ultrastructural and cytochemical studies on cell death of osteoclasts induced by bisphosphonate treatment. Bone. 1999;25:447.10.1016/S8756-3282(99)00197-0]Search in Google Scholar
[37. Marx R. Oral and intravenous bisphosphonate induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2nd ed. New Malden: Quintessence Publishing; 2007.]Search in Google Scholar
[38. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567.10.1016/j.joms.2005.07.01016243172]Search in Google Scholar
[39. Hansen T, Kunkel M, Weber A, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates—Histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med. 2006;35:155.10.1111/j.1600-0714.2006.00391.x16454811]Search in Google Scholar
[40. Pabst AM, Ziebart T, Ackermann M, Konerding MA, Walter C. Bisphosphonates’ antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. Clin Oral Investig. 2014;18:1015.10.1007/s00784-013-1060-x23892503]Search in Google Scholar
[41. McLeod NM, Brennan PA, Ruggiero SL. Bisphosphonate osteonecrosis of the jaw: a historical and contemporary review. Surgeon. 2012;10:36.10.1016/j.surge.2011.09.00222233554]Search in Google Scholar
[42. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? Bone. 2007;41:318.]Search in Google Scholar
[43. Dimopoulos MA, Kastritis E, Bamia C, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-120.10.1093/annonc/mdn55418689864]Search in Google Scholar
[44. Vandone AM, Donadio M, Mozzati M, et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience. Ann Oncol. 2012;23:193-200.10.1093/annonc/mdr03921427065]Search in Google Scholar
[45. Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23.10.1002/jbmr.240525414052]Search in Google Scholar
[46. Lerman MA, Xie W, Treister NS, Richardson PG, Weller EA, Woo SB. Conservative management of bisphosphonate-related osteonecrosis of the jaws: staging and treatment outcomes. Oral Oncol. 2013;49:977-983.10.1016/j.oraloncology.2013.05.01223830962]Search in Google Scholar
[47. Melea PI, Melakopoulos I, Kastritis E, Tesseromatis C, Margaritis V, Dimopoulos MA. Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. Int J Dent. 2014;2014:427273.10.1155/2014/427273408725425045353]Search in Google Scholar
[48. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S. Conservative surgical management of stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent. 2014;2014:107690.10.1155/2014/107690393347324648841]Search in Google Scholar
[49. Romeo U, Galanakis A, Marias C, et al. Observation of pain control in patients with bisphosphonate-induced osteonecrosis using low level laser therapy: Preliminary results. Photomed Laser Surg. 2011;29:447-452.10.1089/pho.2010.283521235406]Search in Google Scholar
[50. Wutzl A, Biedermann E, Wanschitz F, Seemann R, Klug C, Baumann A. Treatment results of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2008;30:1224-1230.10.1002/hed.2086418642292]Search in Google Scholar
[51. Vescovi P, Merigo E, Meleti M, Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. J Oral Pathol Med. 2012;41:214-221.10.1111/j.1600-0714.2011.01091.x21958312]Search in Google Scholar
[52. Martins MA, Martins MD, Lascala CA, Curi MM, Migliorati CA, Tenis CA. Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncol. 2012;48:79-84.10.1016/j.oraloncology.2011.08.01021940198]Search in Google Scholar
[53. Rugani P, Acham S, Kirnbauer B, Truschnegg A, Obermayer-Pietsch B, Jakse N. Stage-related treatment concept of medication-related osteonecrosis of the jaw-a case series. Clin Oral Investig. 2015;19:1329-38.10.1007/s00784-014-1384-125511385]Search in Google Scholar
[54. Carlson ER, Basile JD. The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67(5Suppl):85-95.10.1016/j.joms.2009.01.00619371819]Search in Google Scholar
[55. Brauner E, Guarino G, Jamshir S, et al. Evaluation of highly porous dental implants in postablative oral and maxillofacial cancer patients: A prospective pilot clinical case series report. Implant Dent. 2015;24:631-637.10.1097/ID.000000000000029526115199]Search in Google Scholar
[56. Seth R, Futran ND, Alam DS, Knott PD. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. Laryngoscope. 2010;120:2165-71.10.1002/lary.2106220824743]Search in Google Scholar
[57. Pompa G, Bignozzi I, Cristalli MP, Quaranta A, Di Carlo S. Bisphosphonates and Osteonecrosis of the jaw: The oral surgeon’s perspective. Eur J Inflamm. 2012;101:11-23.10.1177/1721727X1201000102]Search in Google Scholar
[58. Agrillo A, Filiaci F, Ramieri V, Riccardi E, Quarato D, Rinna C. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with ozone therapy. Eur Rev Med Pharmacol Sci. 2012;16:1741–1747.]Search in Google Scholar
[59. Gonzálvez-García M, Rodríguez-Lozano FJ, Villanueva V, Segarra-Fenoll D, Rodríguez-González MA, Oñate-Sánchez R. Cell therapy in bisphosphonate-related osteonecrosis of the jaw. J Craniofac Surg. 2013;24:e226–e228.10.1097/SCS.0b013e318286996823714970]Search in Google Scholar
[60. Cella L, Oppici A, Arbasi M, Moretto M, Piepoli M, Vallisa D. Autologous bone marrow stem cell intralesional transplantation repairing bisphosphonate related osteonecrosis of the jaw. Head Face Med. 2011;7:16.10.1186/1746-160X-7-16317544321849044]Search in Google Scholar
[61. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O. Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg. 2011;69:2465–2472.10.1016/j.joms.2011.02.07821763050]Search in Google Scholar
[62. Cheung A, Seeman E. Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med. 2010;363:2473–2474.10.1056/NEJMc100268420950167]Search in Google Scholar
[63. Neuprez A, Rompen E, Crielaard JM, Reginster JY. Teriparatide therapy for denosumab-induced osteonecrosis of the jaw in a male osteoporotic patient. Calcif Tissue Int. 2014;95:94-96.10.1007/s00223-014-9858-324804929]Search in Google Scholar